Preclinical collaboration with a subsidiary of Merck & Co focused on the development of a vaccine for Respiratory Syncytial Virus (RSV).
The studies will evaluate the combination of Merck’s proprietary RSV antigen with NanoBio’s NanoStat adjuvant technology for use as an intranasal vaccine.
Merck has the option to negotiate a non-exclusive license to the NanoStat adjuvant for development of a commercial RSV vaccine.
Earlier preclinical studies conducted by NanoBio have demonstrated that a NanoStat adjuvanted RSV vaccine induces robust protective immunity, without eliciting the enhanced respiratory disease that has caused other RSV vaccine candidates to fail. “We are very pleased to enter into this collaboration with Merck,” commented James R. Baker, Jr., MD, NanoBio’s Founder & CEO. “RSV remains a major cause of serious lung infections in children and the elderly. We look forward to working together in an effort to advance RSV vaccine research.”
View the full deal record at Current Agreements.